Page
Biosample Repository
The Natural History Database and Biosample Repository has been instrumental in advancing my LAM research. The extensive resources within the database have been valuable for my investigations, and the accessibility
Page
Natural History Database
The Natural History Database is a fantastic resource for research in TSC. It is an incredible resource for those in epidemiology, given its unparalleled size. It is an incredible resource
Page
Run with Team TSC
Team TSC is a dedicated group of people running on behalf of the 50,000 people in the US and 1 million worldwide with tuberous sclerosis complex (TSC). Upcoming Team
Page
Become a member
The TSC Alliance is a membership-based organization, which means members participate in the corporate governance of the organization, which includes electing the Board of Directors. As such, members have a
Page
Government advocacy
Your voice makes a difference! $121 million appropriated for the TSCRP since 2002 $5.725 million to support clinical care and research at TSC centers in four states 120 volunteer advocates
Page
Volunteer
Champion our cause: Join the TSC Alliance volunteer movement! The tuberous sclerosis complex (TSC) community is the TSC Alliance’s strongest ally. We rely on our dedicated volunteers to help drive
Page
Spotlight on TSC Alliance
2024 marks the 50th anniversary of the TSC Alliance®! Throughout the year, we’ll celebrate five decades of progress as well as look forward with much promise for the future. Join
Page
Lungs
Lung involvement is more common in women with TSC than men. The average age of onset is during the childbearing years, although lung involvement can occasionally occur in teenagers with
News Item
0 to 6 months old with TSC needed for research study
Why are we doing this study? Epilepsy is very common in infants diagnosed with tuberous sclerosis complex (TSC) and often very difficult to treat. This study tests if sirolimus, a
TSC Alert
MILED Trial Currently Enrolling Women with LAM
Please circulate the following to your patients with lymphangioleiomyomatosis (LAM): The MILED Trial is a new research study designed to answer the question of whether we should be starting sirolimus